The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Provided herein is a composite microparticle for oral delivery of an active agent to a subject. The microparticles are general in the form of self-sustaining bodies comprising a crosslinked polymer matrix and a plurality of emulsion droplets distributed throughout. The active agent is encapsulated in the emulsion droplets. A plurality of delivery enhancing moieties are presented on the exterior surface of said self-sustaining body and/or on the emulsion droplets. The microparticle is resistant to enteric degradation and will localize in the gastrointestinal tract of the subject without crossing the intestinal mucosa into the intestinal bloodstream.

Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.

It may be one of the aspects of the invention that a drug delivery device for delivery of two or more independently user selectable multiple doses of medicaments contained in separate cartridges of the medicament reservoirs within a single device operatively connected to a single dispense interface which may be operatively connected to a single activation button; It may be another aspect of the invention that unlocking of the user operable variable dose locking mechanism of the drug delivery device may be easily carried out by one hand operation by a lock slider unlock by the user.

The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.

The present invention relates to compounds of formula I:

##STR00001##

for use in treating pulmonary arterial hypertension and associated conditions, where R.sub.1, R.sub.2 and R.sub.3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R.sub.4 signifies hydrogen, alkyl, -alkylaryl or -alkylheteroaryl; X signifies CH.sub.2, oxygen atom or sulphur atom; n is 1, 2 or 3, with the proviso that when n is 1, X is not CH.sub.2; and the individual (R)- and (S)-enantiomers or mixtures of enantiomers and pharmaceutically acceptable salts thereof.

The present invention relates to a pulverulent vitamin formulation in which the vitamin essentially has a particle size of less than 0.7 m and which comprises an effective amount of propyl gallate, and also to processes for producing this formulation, and to formulations obtainable by these processes and to the use thereof as animal feed, food, food supplement, personal care product or pharmaceutical composition. The formulations of the invention have improved stability compared to the prior art.

[Object] An object of the present invention is to provide a QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent. [Method for Achieving the Object] A QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent containing Lactobacillus ONRICb0240 (FERM BP-10065).

Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.